发明Anti-ADDL antibodies and uses thereof

pdf收藏

著录项目

申请号 US20100828411 申请日 2010年07月01日 最早公开日 2010年10月28日 所属国家/地区 美国
公开号及公开日 US2010272714A1   2010年10月28日
US8128930B2   2012年03月06日
授权日 2012年03月06日 说明书附图
申请人 ACTON PAUL (美国)  
AN ZHIQIANG (美国)  
BETT ANDREW J (美国)  
BREESE ROBERT (美国)  
CHANG LEI (美国)  
DODSON ELIZABETH CHEN (美国)  
KINNEY GENE (美国)  
KLEIN WILLIAM (美国)  
LAMBERT MARY P (美国)  
LIANG XIAOPING (美国)  
SHUGHRUE PAUL (美国)  
STROHL WILLIAM R (美国)  
VIOLA KRISTEN (美国)  
发明人 ACTON PAUL   AN ZHIQIANG   BETT ANDREW J   BREESE ROBERT   CHANG LEI   DODSON ELIZABETH CHEN   KINNEY GENE   KLEIN WILLIAM   LAMBERT MARY P   LIANG XIAOPING   SHUGHRUE PAUL   STROHL WILLIAM R   VIOLA KRISTEN  
优先权 US20040621776P   20041025US20050652538P   20050214US20050695528P   20050630US20050695526P   20050630US20050256332   20051021US20100828411   20100701
专利分类号 A61K39/395   C07K16/18   G01N33/53   C07K16/00   C12N5/02  
代理机构   代理人

名称及摘要

Anti-ADDL antibodies and uses thereof
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
Anti-ADDL antibodies and uses thereof
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

同族及引用

同族专利 (20) 引用其他专利(149) 被其他专利引用(32)

CA2584859C ANTI-ADDL ANTIBODIES AND USES THEREOF
WO2006055178A3 ANTI-ADDL ANTIBODIES AND USES THEREOF
AU2005306997B2 Anti-ADDL antibodies and uses thereof
US7780963B2 Anti-ADDL antibodies and uses thereof
NO20072700A Anti-ADDL antibodies and uses thereof
EP1812062A4 ANTI-ADDL ANTIBODIES AND USES THEREOF
IL182554D0 ANTI-ADDL ANTIBODIES AND USES THEREOF
KR20070094890A ANTI-ADDL ANTIBODIES AND USES THEREOF
JP5173426B2 【Title of corresponding document:ep2465872A2】 Anti-ADDL antibodies and uses thereof
US7811563B2 Anti-addl antibodies and uses thereof
BRPI0516962A isolated antibody, or fragment of the same, pharmaceutical composition, methods to prevent the connection of difundìveis ligantes derivatives of abeta to a neurènio, to inhibit the constitution of difundìveis ligantes, to block the fosforila??o of proteìna, to treat prophylactically or therapeutically a disease, to identify a therapeutical agent, to detect difundìveis ligantes, and to diagnose a disease, and, kit to detect difundìveis ligantes
IL190502D0 ANTI-ADDL MONOCLONAL ANTIBODY AND USE THEREOF
RU2007119382A ADDL antibodies against AND THEIR USE
NZ554725A Anti-ADDL antibodies and uses thereof
US8128930B2 Anti-ADDL antibodies and uses thereof
US8889138B2 Anti-ADDL antibodies and uses thereof
JP2012087139A ANTI-ADDL ANTIBODY AND USE THEREOF
JP5634975B2 ANTI-ADDL ANTIBODY AND USE THEREOF
EP2465872A3 Anti-ADDL antibodies and uses thereof
JP2013035843A ANTI-ADDL ANTIBODY AND USE THEREOF
Humanized antibody against amyloid beta
Antibody capable of binding specifically to Abeta-oligomer, and use thereof
Humanized anti-amyloid-b oligomer antibody
Anti-ADDL monoclonal antibody and uses thereof
人源化抗淀粉样-B寡聚体抗体
特异性结合Aβ寡聚体的抗体及其用途
NEUTRALIZING ANTI-CCL20 ANTIBODIES
ANTI-ADDL MONOCLONAL ANTIBODIES AND USE THEREOF
Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR 1
HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1
ANTI-IL-13R ALPHA 1 ANTIBODIES AND THEIR USES THEREOF
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
New use of glutaminyl cyclase inhibitors
Humanized antibody against amyloid beta.
Anti-IL-13R alpha 1 antibodies and their uses thereof
Thiourea derivatives as glutaminyl cyclase inhibitors
ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO AB-OLIGOMER, AND USE THEREOF
HUMANIZED ANTIBODY AGAINST AMYLOID BETA
HUMANIZED ANTIBODY
【Title of corresponding document:ep2829551A1】 High affinity antibody antagonists of interleukin-13 receptor alpha 1
【Title of corresponding document:CA2666682A1】 ANTI-IL-13R.ALPHA.1 ANTIBODIES AND THEIR USES THEREOF
【Title of corresponding document:CA2667067A1】 ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR A1
【Title of corresponding document:ep2210901A1】
Diagnostic and treatment of disease and other cerebrovascular neurocyte Alzheimer hyperlipidemia
【Title of corresponding document:ep2463368A1】
【Title of corresponding document:ep2463369A1】
ANTI-ADDL ANTIBODY AND USE THEREOF
【Title of corresponding document:CN102596997A】 Antibodies that specifically bind to A beta oligomers and use thereof
【Title of corresponding document:CN102574915A】 Antibodies that specifically bind to A beta oligomers and use thereof
HIGH AFFINITY ANTIBODY ANTAGONIST OF INTERLEUKIN-13 RECEPTOR ALPHA 1
【Title of corresponding document:CN103140500A】 Anti-addl monoclonal antibody and uses thereof
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
Antibody treatment of Alzheimer's and related diseases
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
Humanized anti-amyloid antibody
Protofibril selective antibodies and the use thereof
Anti-IL-13Ralpha1 antibodies and their uses thereof
Antibody antagonists of interleukin-13 receptor α1
Arctic β amyloid protofibril
Methods of modifying amyloid β oligomers using non-peptidic compounds
Methods of restoring cognitive ability using non-peptidic compounds
Inhibition of factor B, the alternative complement pathway and methods related thereto
Inhibition of factor B, the alternative complement pathway and methods related thereto
Human monoclonal anti-amyloid-beta antibodies
Humaneered anti-factor B antibody
Monoclonal antibody
Peptide compounds for treating obesity and insulin resistance
TARGETED INDUCTION OF AGGREGATION OF PROTEINS WITH CROSS BETA STRUCTURES
USE OF A CAMELID SINGLE-DOMAIN ANTIBODY FOR DETECTING AN OLIGOMERIC FORM OF AN AMYLOID BETA PEPTIDE AND ITS APPLICATIONS
HUMANIZED ANTIBODY
Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
Anti-factor XI monoclonal antibodies and methods of use thereof
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
Anti-amyloid antibodies and uses thereof
ANTI-AMYLOID IMMUNOGENIC COMPOSITIONS, METHODS AND USES
Compounds for treating beta-amyloidoses
Antibody Specific Binding to A Beta Oligomer and the Use
Anti-Aβ oligomer humanized antibody
Anti-Aβ oligomer humanized antibody
Antibody Fc mutants with ablated effector functions
Antibodies that specifically bind to A beta oligomers and use thereof
Anti-GITR antibodies
Antibodies that specifically bind to A beta oligomers and use thereof
Antibodies that specifically bind to a beta oligomers and use thereof
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody
Methods for identifying safe and functional humanized antibodies
Antibodies specific for amyloid beta protofibril
Protofibril selective antibodies and the use thereof
Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
Neutralizing anti-CCL20 antibodies
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
Antibodies that specifically bind to Aβ oligomers and uses thereof
Methods for increasing efficacy of FOLR1 cancer therapy
Polynucleotides encoding anti-factor XI monoclonal antibodies and methods of use thereof
Antibodies, kit and method for detecting amyloid beta oligomers
Nucleic acid molecules encoding a humanized antibody
Antibody formulations and methods
Anti-A(β) oligomer humanized antibody
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
Humaneered anti-factor B antibody
Compositions for binding to amyloid proteins
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
Compositions and methods for treating neoplasia
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Biological complex specific for Alzheimer's disease detection in vitro and use thereof
Nucleic acids encoding neutralizing anti-CCL20 antibodies
Diagnostic assays and kits for detection of folate receptor 1
Monoclonal antibody
Humaneered anti-factor B antibody
Anti-factor XI monoclonal antibodies and methods of use thereof
Anti-GITR antibodies
Anti-ADDL monoclonal antibody and uses thereof
Monoclonal antibodies for detection of folate receptor 1
Antibodies obtainable using supramolecular constructs
Antibody Fc mutants with ablated effector functions
Amyloid-beta binding proteins
Antibodies, kit and method for detecting amyloid beta oligomers
Aβ protofibril binding antibodies
Anti-factor XI monoclonal antibodies and methods of use thereof
Neutralizing anti-CCL20 antibodies
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Methods for treating neoplasia
Polynucleotides encoding anti-amyloid beta monoclonal antibodies
Diagnostic assays and kits for detection of folate receptor 1
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Folate receptor 1 antibodies and immunoconjugates and uses thereof
Antibody formulations and methods for treating AL amyloidosis
Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
HUMANIZED ANTIBODY AGAINST AMYLOID BETA
ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR a1
NEW USE OF GLUTAMINYL CYCLASE INHIBITORS
USE OF A CAMELID SINGLE-DOMAIN ANTIBODY FOR DETECTING AN OLIGOMERIC FORM OF AN AMYLOID BETA PEPTIDE AND ITS APPLICATIONS
ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO A? OLIGOMER, AND USE THEREOF
ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO A?-OLIGOMER, AND USE THEREOF
METHODS FOR PURIFYING ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY
HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMERS AND USE THEREOF
HUMANIZED ANTI-AMYLOID-? OLIGOMER ANTIBODY
HUMANIZED ANTI-AMYLOID-? OLIGOMER ANTIBODY
ANTI-AMYLOID BETA ANTIBODIES CONJUGATED TO SIALIC ACID-CONTAINING MOLECULES
ANTI-GITR ANTIBODIES
INHIBITORS OF GLUTAMINYL CYCLASE
HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5)
BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE
READTHROUGH ACETYLCHOLINESTERASE (ACHE-R) FOR TREATING OR PREVENTING PARKINSON'S DISEASE
FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF
ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
SAFE AND FUNCTIONAL HUMANIZED ANTI BETA-AMYLOID ANTIBODY
NEUTRALIZING ANTI-CCL20 ANTIBODIES
BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE
ANTIBODIES TO PHOSPHORYLATED TAU AGGREGATES
STANDARD FOR QUANTIFYING PATHOGENIC AGGREGATES FROM PROTEINS PRODUCED NATURALLY IN THE BODY
METHOD FOR DETECTION OF AMYLOID BETA OLIGOMERS IN A FLUID SAMPLE AND USES THEREOF
ANTIBODIES, KIT AND METHOD FOR DETECTING AMYLOID BETA OLIGOMERS
A BIOLOGICAL COMPLEX SPECIFIC FOR ALZHEIMER'S DISEASE DETECTION IN VITRO AND USE THEREOF
VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE
HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
CAR T-CELLS FOR THE TREATMENT OF B7-H4 EXPRESSING SOLID TUMORS
NOVEL AMYLOID BETA OLIGOMER SPECIFIC BINDING MOLECULE
ANTI-RYK ANTIBODIES AND METHODS OF USING THE SAME
Pharmaceutical screens and antibodies.
Modified lipopolysaccharides and process of preparation
REDUCTION IN IMMUNOGENICITY OF VARIABLE DOMAIN OF ANTIBODY
【Title of corresponding document:CA2279555A1】 AMYLOID BETA PROTEIN (GLOBULAR ASSEMBLY AND USES THEREOF)
【Title of corresponding document:CA2326501A1】 BINDING MOLECULES DERIVED FROM IMMUNOGLOBULINS WHICH DO NOT TRIGGER COMPLEMENT MEDIATED LYSIS
【Title of corresponding document:ep2465872A2】 Anti-ADDL antibodies and uses thereof
Purified and antigenically selective vaccines for domestic animals
Humanized immunoglobulins
Amyloid beta protein (globular assembly and uses thereof)
Multivalent and multispecific binding proteins and their use
Passive immunization treatment of Alzheimer's disease
N-Terminal amyloid-beta antibodies
Humanized and chimeric N-terminal amyloid beta-antibodies
Passive immunization treatment of alzheimer's disease
Method for reducing the immunogenicity of antibody variable domains
Anti-ADDL antibodies and uses thereof
Passive immunization of Alzheimer's disease
CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
ADJUVANT FORMULATION COMPRISING A SUBMICRON OIL DROPLET EMULSION
METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
GENERATION OF XENOGENEIC ANTIBODIES
RECOMBINANT LIBRARY SCREENING METHODS
TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
PORCINE CELL INTERACTION PROTEINS
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
ANTIBODY VARIANTS AND FRAGMENTS THEREOF
ANTI-ADDL ANTIBODIES AND USES THEREOF
ANTIBODIES SPECIFIC FOR TOXIC AMYLOID BETA PROTEIN OLIGOMERS
MONOCLONAL ANTIBODIES SPECIFIC FOR CONFORMATIONAL EPITOPES OF PREFIBRILLAR AGGREGATES

法律状态历史( 到官方网站查询 )

2010年07月01日 us_idsc (更多信息: Information Disclosure Statement considered , IDSC)
2010年07月01日 us_m844 (更多信息: Information Disclosure Statement (IDS) Filed , M844)
2010年07月01日 us_crfl (更多信息: CRF Disk Has Been Received by Preexam / Group / PCT , CRFL)
2010年07月01日 us_wids (更多信息: Information Disclosure Statement (IDS) Filed , WIDS)
2010年07月01日 us_scan (更多信息: IFW Scan & PACR Auto Security Review , SCAN)
2010年07月01日 us_iexx (更多信息: Initial Exam Team nn , IEXX)
2010年07月02日 us_l198 (更多信息: Referred to Level 2 (LARS) by OIPE CSR , L198)
2010年07月07日 us_l128 (更多信息: Cleared by L&R (LARS) , L128)
2010年07月16日 us_crfe (更多信息: CRF Is Good Technically / Entered into Database , CRFE)
2010年07月20日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2010年07月20日 us_comp (更多信息: Application Is Now Complete , COMP)
2010年07月20日 us_oipe (更多信息: Application Dispatched from OIPE , OIPE)
2010年07月20日 us_flrcpt.o (更多信息: Filing Receipt , FLRCPT.O)
2010年08月03日 us_dock (更多信息: Case Docketed to Examiner in GAU , DOCK)
2010年08月05日 us_as 转让(新专利权人: MERCK & CO.,INC.,NEW JERSEY
更多信息: CORRECTIVE ASSIGNMENT TO CORRECT THE TYPOGRAPHICAL ERROR IN ZHIQIANG AN'S NAME ON ORIGINAL COVERSHEET PREVIOUSLY RECORDED ON REEL 017994 FRAME 0922. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT SPELLING IS ZHIQIANG AN (NOT ZHIGIANG AN);ASSIGNORS:ACTON,PAUL;AN,ZHIQIANG;BETT,ANDREW J.;AND OTHERS;SIGNING DATES FROM 20060605 TO 20060612;REEL/FRAME:024792/0856)
2010年08月05日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2010年08月06日 us_a.pe (更多信息: Preliminary Amendment , A.PE)
2010年10月28日 us_pg-issue (更多信息: PG-Pub Issue Notification , PG-ISSUE)
2010年11月02日 us_dock (更多信息: Case Docketed to Examiner in GAU , DOCK)
2011年10月20日 us_ex.r (更多信息: Reasons for Allowance , EX.R)
2011年10月26日 us_mn/=. (更多信息: Mail Notice of Allowance , MN/=.)
2011年10月26日 us_dock (更多信息: Case Docketed to Examiner in GAU , DOCK)
2011年10月26日 us_n/=. (更多信息: Notice of Allowance Data Verification Completed , N/=.)
2011年11月14日 us_crft (更多信息: Sequence Forwarded to Pubs on Tape , CRFT)
2011年12月08日 us_mm327-d (更多信息: Mail PUB other miscellaneous communication to applicant , MM327-D)
2011年12月08日 us_m327-d (更多信息: PUB Other miscellaneous communication to applicant , M327-D)
2011年12月09日 us_as 转让(新专利权人: NATIONAL INSTITUTES OF HEALTH (NIH),U.S. DEPT. OF
更多信息: CONFIRMATORY LICENSE;ASSIGNOR:NORTHWESTERN UNIVERSITY;REEL/FRAME:027359/0112
生效日期: 20111117)
2011年12月19日 us_as 转让(新专利权人: MERCK SHARP & DOHME CORP.,NEW JERSEY
更多信息: CHANGE OF NAME;ASSIGNOR:MERCK & CO.,INC.;REEL/FRAME:027407/0910
生效日期: 20091102)
2011年12月22日 us_a.na (更多信息: Amendment after Notice of Allowance (Rule 312) , A.NA)
2011年12月22日 us_drwf (更多信息: Workflow - Drawings Finished , DRWF)
2012年01月03日 us_pubtc (更多信息: Pubs Case Remand to TC , PUBTC)
2012年01月04日 us_mn271 (更多信息: Mail Response to 312 Amendment (PTO-271) , MN271)
2012年01月04日 us_n271 (更多信息: Response to Amendment under Rule 312 , N271)
2012年01月13日 us_let. (更多信息: Miscellaneous Incoming Letter , LET.)
2012年01月13日 us_tcpb (更多信息: Printer Rush- No mailing , TCPB)
2012年01月19日 us_n084 (更多信息: Issue Fee Payment Verified , N084)
2012年01月19日 us_ifee (更多信息: Issue Fee Payment Received , IFEE)
2012年01月24日 us_pils (更多信息: Application Is Considered Ready for Issue , PILS)
2012年01月31日 us_d1935 (更多信息: Dispatch to FDC , D1935)
2012年02月15日 us_wpir (更多信息: Issue Notification Mailed , WPIR)
2012年03月06日 us_pgm/ (更多信息: Recordation of Patent Grant Mailed , PGM/)
2012年03月06日 us_ptac (更多信息: Patent Issue Date Used in PTA Calculation , PTAC)
2012年03月12日 us_crfa (更多信息: Sequence Moved to Public Database , CRFA)
2012年08月27日 us_as 转让(新专利权人: SCHERING CORPORATION,NEW JERSEY
更多信息: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:028850/0515
生效日期: 20120426)
2012年08月29日 us_as 转让(新专利权人: MERCK SHARP & DOHME CORP.,NEW JERSEY
更多信息: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028866/0511
生效日期: 20120502)
2012年08月30日 us_as 转让(新专利权人: NATIONAL INSTITUTES OF HEALTH (NIH),U.S. DEPT. OF
更多信息: CONFIRMATORY LICENSE;ASSIGNOR:NORTHWESTERN UNIVERSITY;REEL/FRAME:028884/0883
生效日期: 20111117)
2015年08月19日 us_fpay 缴费(付费年限: 4)

更新记录

2014年06月20日